FT. LAUDERDALE, Fla., May 6, 2010 (GLOBE NEWSWIRE) -- New preclinical data demonstrating the antiviral activity and stability of NovaBay Pharmaceuticals’ (AMEX:NBY) Aganocide® compounds were presented during three poster sessions at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting in Ft. Lauderdale, Florida this week.
